Aclaris Therapeutics, Inc.

ACRS · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$14,614-$15,429-$15,085-$96,552
Dep. & Amort.$210$114$128$143
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$3,063$3,535$2,860
Change in WC$612$759-$1,935-$994
Other Non-Cash$2,860$1,500$300$85,605
Operating Cash Flow-$10,932-$9,993-$13,057-$8,938
Investing Activities
PP&E Inv.-$23-$21-$43-$35,810
Net Acquisitions$0$0$0$0
Inv. Purchases-$5,198-$19,930-$9,996-$70,427
Inv. Sales/Matur.$19,051$24,998$29,991$17,514
Other Inv. Act.$0$0-$833$0
Investing Cash Flow$13,830$5,047$19,119-$88,723
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0$74,913
Stock Repurch.$0-$9-$275$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$3,044$0$0-$333
Financing Cash Flow-$3,044-$9-$275$74,580
Forex Effect$0$0$0$0
Net Chg. in Cash-$146-$4,955$5,787-$23,081
Supplemental Information
Beg. Cash$25,402$30,357$24,570$47,651
End Cash$25,256$25,402$30,357$24,570
Free Cash Flow-$10,955-$10,014-$13,100-$44,748
Aclaris Therapeutics, Inc. (ACRS) Financial Statements & Key Stats | AlphaPilot